2021 ~ Present

• - Preclinical study evaluation completed
• - Nonclinical trial preparation
• - License-out and collaborative research with Dong-A ST
• - Selected for government-supported research hospital programs
• - 2 new patents pending
• - Patents registered in U.S., Russia, and Australia
• - Named among Baby Unicorns 200
• - Bridge round completed
• - Nonclinical toxicology evaluation completed
• - Phase I and II preparations for IND
• - Collaborative research agreement with SK Chemicals, HK InnoN, Samjin Pharmaceutical

2019 ~ 2020

• - Series A
• - Second-generation platform technology developed
• - GLP toxicology studies
• - 2 patent registrations, entering 9 countries
• - Agreements with domestic and international pharmaceutical companies

2017 ~ 2018

• - Enterprise Laboratory certification earned
• - First-generation platform technology developed
• - Venture enterprise certified
• - Research collaboration contract signed with Asan Medical Center, Seoul

2016

• - ONCOBIX Inc. established